• EPH29 Budget Impact of an Organized Cervical Cancer Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • HTA168 Harmonization or Hindrance? A Strategic Analysis of Divergent National Requirements Under the EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • HTA75 Clinical Benefit vs. Reimbursement Decisions: Examining Misalignments Between ESMO-MCBS and HTA Outcomes in Oncology

    Dec 1, 2025, 00:00

  • EE445 Evaluating the Impact of Subsequent Anticancer Therapy Use on Life-Year and QALY Estimates in Late-Line Metastatic Colorectal Cancer: A Health Economic Analysis of FRESCO-2

    Dec 1, 2025, 00:00

  • MSR172 Predictive Algorithms in HTA: What Factors Influence Decision Making in NICE, SMC, and NCPE?

    Dec 1, 2025, 00:00

  • RWD18 Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data

    Dec 1, 2025, 00:00

  • PCR228 The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies

    Dec 1, 2025, 00:00

  • HPR56 Disparities in Access to Gene Therapy in the European Union: Ethical and Regulatory Challenges

    Dec 1, 2025, 00:00

  • HPR7 A Decade of Change in Turkish Healthcare Utilization: Hospital Admission Trends 2015-2024

    Dec 1, 2025, 00:00

  • PCR19 Are We Measuring What Matters in Postpartum Depression Trials?

    Dec 1, 2025, 00:00

  • PCR213 Sex Differences in Patients With Chronic Hand Eczema (CHE): Disease Manifestations and Quality of Life (QoL) Results From a Cross-Sectional Multinational Study

    Dec 1, 2025, 00:00

  • EE668 Spain Leveling Up: A Comparison of Spain’s New National Health Economic Evaluation Guideline With Those of England, France, Germany, Italy, Portugal, Sweden, Ireland, Canada, Australia, and Japan

    Dec 1, 2025, 00:00

  • CO209 Real-World Treatment Patterns and Outcomes in First-Line Small-Cell Lung Cancer (SCLC) in France

    Dec 1, 2025, 00:00

  • EPH97 Evolution and Geographical Patterns of the Portuguese Newborn Screening Program in the Last 10 Years

    Dec 1, 2025, 00:00

  • MSR116 Give Us the Tools and We Will Finish the Job: How Accurate Is AI for Study Selection in Systematic Reviews?

    Dec 1, 2025, 00:00

  • HSD108 The Micro-Meso-Macro (3M) Impact Framework: Capturing Health System Value Across Interacting Levels

    Dec 1, 2025, 00:00

  • CO187 Preventing Bleeds in Pediatric Patients With Hemophilia A: Which Factor Replacement Therapy Offers the Best Protection and at What Cost?

    Dec 1, 2025, 00:00

  • SA24 Cost Variation Across Lung-Cancer Diagnostic-Pathway Clusters: A Nationwide Real-World Analysis of 18,569 French Patients

    Dec 1, 2025, 00:00

  • CO92 Efficacy and Safety of Inhaled Levofloxacin vs. Other Inhaled Antibiotics in the Treatment of Adults With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection: An Updated Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EE333 Direct Medical Costs of Home-Based Respiratory Support and Oxygen Therapy for Patients With Chronic Respiratory Failure

    Dec 1, 2025, 00:00

  • CO228 Systematic Literature Review of Artificial Intelligence-Based Models Predicting COPD Exacerbations

    Dec 1, 2025, 00:00

  • OP24 Turning SAP Feedback into HTA-Ready Action: A Semi-Automated Approach for RWD Studies

    Dec 1, 2025, 00:00

  • MSR7 A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France

    Dec 1, 2025, 00:00

  • PCR112 Health-Related Quality of Life (HRQoL) and Its Associated Factors among Chinese Gout Patients: Baseline Findings From a Survey Study

    Dec 1, 2025, 00:00

  • HPR156 Payer and HTA Evaluation Criteria and Considerations for Coverage and Reimbursement of Patient Self-Monitoring Technology

    Dec 1, 2025, 00:00

  • EE77 Bridging the Gap: Why Cost-Effectiveness Analyses of Congenital Heart Interventions Are Critical for Person-Centered Value-Based Care

    Dec 1, 2025, 00:00

  • EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status

    Dec 1, 2025, 00:00

  • MT36 Quantifying the Impact of Data Digital and AI on Health Systems

    Dec 1, 2025, 00:00

  • PT21 Can Generative AI Deliver Patient-Friendly Summaries? A Case Study Using NICE Guidance for Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • EE633 Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective

    Dec 1, 2025, 00:00

  • MSR20 AI Powered SQL for Real-World Data: From Questions to Insights

    Dec 1, 2025, 00:00

  • EE474 First-Trimester Screening for Preterm Pre-Eclampsia in the United Kingdom: A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EPH132 Identifying Risk Factors Associated With Meningioma: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR79 Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Lung Cancer Patients Using Machine Learning

    Dec 1, 2025, 00:00

  • PT16 Patients’ Advocacy Groups in Italy: An Updated Perspective on Activities and Future Directions

    Dec 1, 2025, 00:00

  • EE444 Evaluating the Impact of Different Payment Models on the Cost-Effectiveness and Budget Impact of Cell and Gene Therapies: Eladocagene Exuparvovec As a Case Study

    Dec 1, 2025, 00:00

  • EE557 Integrating Environmental Sustainability Into Cost-Effectiveness Analysis and Value Demonstration: A Multidimensional Framework

    Dec 1, 2025, 00:00

  • EE194 Cost-Effectiveness Analysis of Cariprazine vs. Risperidone for the Treatment of Schizophrenia With Predominantly Negative Symptoms (PNS) in United Arab Emirates

    Dec 1, 2025, 00:00

  • PCR135 Improving Patient Involvement in Cancer Clinical Trials: Development of Plain Language Checklists Within the SISAQOL-IMI Initiative

    Dec 1, 2025, 00:00

  • EE562 Is Less More? Aggregating Health States in State Transition Models

    Dec 1, 2025, 00:00

  • HTA171 Health Equity Considerations in Economic Evaluation: Comparative Acceptability and Application Across European HTA Bodies

    Dec 1, 2025, 00:00

  • CO6 Addressing Clinical Uncertainties in ATMP Reimbursement: A Review of European Methodological Guidelines and Practices

    Dec 1, 2025, 00:00

  • HTA240 National Implementation of the EU HTA Regulation: Progress and Strategic Developments Across Member States

    Dec 1, 2025, 00:00

  • EE534 Impact of Inclusion of Drug Adherence on Cost-Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients

    Dec 1, 2025, 00:00

  • CO124 Gaps in Cancer Screening Uptake in Ireland: Trends, Barriers and Policy Implications

    Dec 1, 2025, 00:00

  • PT22 Advanced Therapy Medicinal Products From Promise to Practi Understanding Reimbursement and Access Disparities in Western Europe

    Dec 1, 2025, 00:00

  • EPH185 Predictors of Effectiveness of Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • HPR219 Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis

    Dec 1, 2025, 00:00

  • EE488 Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France

    Dec 1, 2025, 00:00

  • EE345 Early Adoption of New Combination Biologic Therapy Enabled by Enhanced Diagnostic Accuracy in Inflammatory Bowel Disease (IBD) Can Be a Budget-Neutral Approach: A Budget Impact Analysis in Italy

    Dec 1, 2025, 00:00

  • CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2025, 00:00

  • HTA25 Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration as an Additional Value Driver

    Dec 1, 2025, 00:00

  • HTA152 From GVD to HTA: Preparing for Success in the EU JCA Era With GenAI-Enhanced Efficiency

    Dec 1, 2025, 00:00

  • EE429 Estimation of Utility Weights for Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent Bruton Kinase Inhibitor (cBTKi)

    Dec 1, 2025, 00:00

  • EPH53 Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay

    Dec 1, 2025, 00:00

  • HSD50 Examination of Muscle Activity Among Aesthetic Sports Athletes

    Dec 1, 2025, 00:00

  • EE514 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the United Arab Emirates

    Dec 1, 2025, 00:00

  • EE22 A Model-Based Analysis of the Impact on Labor Market Supply From Enhanced Tobacco Control Strategies in Denmark

    Dec 1, 2025, 00:00

  • SA53 Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older

    Dec 1, 2025, 00:00

  • EPH125 High All-Cause Hospitalization Among Those With Recurrent ASCVD Event: Evidence From a Large-Scale Real-World Database

    Dec 1, 2025, 00:00

  • RWD80 Evolution of Utilization and Costs of Long-Acting Injectable Antipsychotics (LAIs) in Outpatient Care at Lisbon Psychiatric Hospital (March-May 2022 vs. 2025)

    Dec 1, 2025, 00:00

  • RWD14 AI-Assisted Expert Computable Operation Definition (CODef) Development for Real-World Research

    Dec 1, 2025, 00:00

  • SA32 Developing Best Practice for Using Automation Tools in Literature Reviews

    Dec 1, 2025, 00:00

  • CO179 Pharmacist-Led Education Improves Inhaler Satisfaction Adherence and Asthma Control in Asthma Patients

    Dec 1, 2025, 00:00

  • HTA80 Comparator Misalignment As a Contributor to Negative Reimbursement Decisions for Pharmaceuticals in Sweden

    Dec 1, 2025, 00:00

  • HTA58 Bridging the Uncertainty: Cancer Drugs Fund Entry and Exit Outcomes Over Three Years

    Dec 1, 2025, 00:00

  • HPR185 Small Molecules vs. Biologics Patterns of Indication Expansion and the Potential Impact of Medicare Price Negotiation

    Dec 1, 2025, 00:00

  • OP8 Frameworks for the Use of AI Within HEOR: A Targeted Literature Review and Thematic Analysis

    Dec 1, 2025, 00:00

  • SA39 Evaluating the Public Health Impact of Adolescent Meningococcal B (MenB) Vaccination in Fran A Modeling Approach

    Dec 1, 2025, 00:00

  • EPH248 The Incidence, Mortality, and Survival of Metastatic Colorectal Cancer (CRC) per TNM Stages in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • PT18 Evaluating AI Chatbot Empathy and Probing Skills in Automated Patient In-Trial Interviews: A Proof of Principle Experiment

    Dec 1, 2025, 00:00

  • MT11 Cost Analysis of the Extravascular Implantable Cardioverter-Defibrillator Compared to the Subcutaneous System in Patients at Risk of Sudden Cardiac Death in Italy

    Dec 1, 2025, 00:00

  • MSR66 Dealing With Missing Data in Health Economic Studies of Small to Moderate Size: How to Minimize Bias

    Dec 1, 2025, 00:00

  • HTA40 Are We There Yet? Mapping Member State Readiness for Local Implementation of the EU Health Technology Assessment (HTA) Regulation

    Dec 1, 2025, 00:00

  • EE360 Economic Burden of Gaucher Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE88 Budget Impact Analysis of Inclisiran for the Management of Patients With Atherosclerotic Cardiovascular Disease in India: A Multipayer Analysis

    Dec 1, 2025, 00:00

  • EE536 Impact of Maternal Vaccination Strategy on RSV-Related Hospital Burden Among Infants Aged Less Than One Year in Fran A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • PCR155 Measuring Quality of Life in Huntington’s Disease Using a Proxy Approach: Validation of the HD-mQoL-prx Measure

    Dec 1, 2025, 00:00

  • RWD129 Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018-2022

    Dec 1, 2025, 00:00

  • PCR146 Involving Women With Lived Experience of Pelvic Organ Prolapse in Designing and Refining the Economic Components of a Health Technology Assessment

    Dec 1, 2025, 00:00

  • EPH109 Exploring the Impact of Socioeconomic Factors on COVID-19 Vaccine Hesitancy in India: What Can We Learn From the COVID-19 Pandemic? A Scoping Review

    Dec 1, 2025, 00:00

  • HPR28 Are We Getting Good Value for Innovative Therapies in the US? Findings From Generalized Cost-Effectiveness Analyses (GCEAs)

    Dec 1, 2025, 00:00

  • EE475 Five-Year Clinical and Economic Impact of 20 Weight Loss in Adults With Obesity in Saudi Arabia: A Public Healthcare Perspective

    Dec 1, 2025, 00:00

  • RWD158 Real-World Healthcare Resource Utilization and Related Costs Associated With Bladder Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • HPR234 Utilization of Best-Value Medicines for Teriparatide in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • EE280 Cost-Effectiveness of TEVAR With Active Control in Patients With TAA and TBAD: A Japanese Public Healthcare Payer Perspective

    Dec 1, 2025, 00:00

  • MSR64 Country-Related Differential Item Functioning in the EQ-5D-5L: Insights From the EuroQol Data Assessment of Population Health Needs and Instrument Evaluation (EQ-DAPHNIE)

    Dec 1, 2025, 00:00

  • RWD21 Assessing the Feasibility of the Implementation of a Subscription Model Pricing Solution Aimed at Broadening Access to All Eligible Patients Within the HER2 Indication

    Dec 1, 2025, 00:00

  • EE72 BFM 2009 (Berlin, Frankfurt, Munich) Protocol Cost Analysis for Childhood Acute Lymphoblastic Leukemia (ALL): Preliminary Real-World Data From Brazil/LATAM/LMIC

    Dec 1, 2025, 00:00

  • PCR202 Quality of Life in Patients With Severe Hemophilia A With Inhibitors Treated With Emicizumab in Mexico

    Dec 1, 2025, 00:00

  • HTA306 Surrogate Endpoints in German Health Technology Assessment: Post Hoc Analyses of the Phase III PROTECT Study Highlight the Efficacy of Sparsentan in Slowing Down the Loss of Kidney Function in IgAN Patients

    Dec 1, 2025, 00:00

  • MSR55 Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data

    Dec 1, 2025, 00:00

  • RWD189 Use of Big Data to Assess Dyslipidemia Management in Gree Real-World Insights From the National Healthcare Payer

    Dec 1, 2025, 00:00

  • HTA364 What Has Worked Well in Fabry Disease? An HTA Landscape Assessment Study

    Dec 1, 2025, 00:00

  • EE688 The Clinical Humanistic and Economic Burden of the Current Management of Patients With Recurrent Malignant Ascites in the UK and Europe

    Dec 1, 2025, 00:00

  • HTA220 Life Years Generated for Relapsed/Refractory Mantle Cell Lymphoma Patients Managed on CAR-T in an England NHS Setting

    Dec 1, 2025, 00:00

  • RWD67 Disproportionality Analysis Of Vedolizumab to Identify a Putative Signal Using Real-World Postmarketing Surveillance Data Reported in the FAERS Database

    Dec 1, 2025, 00:00

  • EE319 Decluttering Complexity: A Pragmatic Framework for Simplifying Global Health Economic Models for HTA

    Dec 1, 2025, 00:00

  • EPH154 Knowledge and Awareness of Primary Care Physicians (PCPs) Towards Respiratory Syncytial Virus (RSV) in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan

    Dec 1, 2025, 00:00

  • HTA111 Differential HTA Recommendations for Continuous Glucose Monitors (CGMs): A Global Comparative Review of HTA Focus, Challenges, and Solutions

    Dec 1, 2025, 00:00

  • HTA243 Navigating HTA and Innovation: Oncologists’ Perspectives on Access to Cancer Therapies in Bulgaria

    Dec 1, 2025, 00:00

  • SA104 When Trials Don’t Meet: A Retrospective Statistical Analysis Using Matching-Adjusted Indirect Comparison (MAIC) and Individual Patient Data (IPD) to Compare Catiolanze® With Other Preservative-Free (PF) Latanoprost in Open-Angle Glauc ...

    Dec 1, 2025, 00:00

  • HTA23 Addressing Payer Concerns: Opportunities for HEOR in Orphan Drug Development

    Dec 1, 2025, 00:00

  • HTA120 Economic Assessments of Rare Disease Drugs in Fran Insights From CEESP Opinions Reviews

    Dec 1, 2025, 00:00

  • HPR91 Factors Associated With Positive Cost-Effectiveness Judgments in HIRA Drug Reimbursement Decisions: An 8-year Retrospective Review

    Dec 1, 2025, 00:00

  • SA54 Indirect Comparison of Tarlatamab vs. Chemotherapy (CTx) in Patients With Previously Treated, Platinum-Refractory, or Resistant Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • MSR33 Are Economic Models in R That Shiny? Making Cost-Effectiveness Models Shinier by Integrating Artificial Intelligence Applications

    Dec 1, 2025, 00:00

  • EE294 Cost-Substitution and Hospital Diagnosis-Related Group (DRG) Performance Impact Analysis of Infliximab Biosimilar Adoption in Moderate-to-Severe Crohn's Disease Patients in China

    Dec 1, 2025, 00:00

  • EE356 Economic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • CO131 Health-Related Quality of Life (HRQoL) in Duchenne Muscular Dystrophy (DMD): Insights From the DMD-QoL Instrument in the United States (US)

    Dec 1, 2025, 00:00

  • SA78 Quality of Systematic Reviews With Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 Scale

    Dec 1, 2025, 00:00

  • MSR114 Generalizability of a Randomized Clinical Trial-Based Prediction Model in a Real-World Population

    Dec 1, 2025, 00:00

  • RWD33 Clinical and Economic Characteristics of eGFR-Mutated NSCLC Patients Treated With TKIs in South Korea: A Retrospective Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • EPH37 Cardiovascular Implications of Loneliness and Social Isolation: Evidence From a Systematic Review

    Dec 1, 2025, 00:00

  • HTA365 What Is Driving the Increase in Terminated NICE Appraisals?

    Dec 1, 2025, 00:00

  • CO146 Improving Colorectal Cancer Surgical Outcomes Through Audit and Feedback: Results From the Emilia Romagna ESCA Program

    Dec 1, 2025, 00:00

  • PCR191 Preferences for a Combination Influenza and COVID-19 Vaccine: Results From a Stated-Preference Survey With Consumers in the United States, United Kingdom, and Germany

    Dec 1, 2025, 00:00

  • HTA206 Integrating Patient Perspectives in HTA: What Can We Learn to Inform HTA-Focused Value Communications?

    Dec 1, 2025, 00:00

  • PCR10 A Review of Information Uncertainty in Oncology Treatment Preferences

    Dec 1, 2025, 00:00

  • EE320 Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?

    Dec 1, 2025, 00:00

  • EE302 Cost-Utility Analysis of Iptacopan for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With C5 Inhibitor in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EE505 Healthcare Resource Use and Direct Healthcare Costs Associated With Respiratory Syncytial Virus Infections in Individuals Aged 18 Years or Older in Italy: A Retrospective Observational Study

    Dec 1, 2025, 00:00

  • PCR86 Evaluation of the Effectiveness of a Naturalness Probe for Assessing Human- and Nonhuman-Generated COA Translations in Linguistic Validation Cognitive Debriefing Interviews

    Dec 1, 2025, 00:00

  • EE110 Budget Impact of Metyrapone for the Treatment of Cushing’s Syndrome in France

    Dec 1, 2025, 00:00

  • MSR152 Natural History of Creutzfeldt-Jakob Disease: A Comparison of Manual vs. Manual Plus AI-Assisted Approaches in Literature Review

    Dec 1, 2025, 00:00

  • HTA37 Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in Fran A Use Case in Rare Diseases

    Dec 1, 2025, 00:00

  • HPR81 Evolution of National Price Negotiations for Pharmacy/Retail Medicines (Triparty Negotiations) in Sweden and Implications for Access

    Dec 1, 2025, 00:00

  • EE508 Healthcare Resource Utilization (HCRU) Analysis in Newly Diagnosed Mantle Cell Lymphoma: Autologous Stem Cell Transplantation (ASCT) and (HCRU) Alleviation With Adoption of the TRIANGLE Ibrutinib Regimen Without (ASCT)

    Dec 1, 2025, 00:00

  • EE540 Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain

    Dec 1, 2025, 00:00

  • EE593 Multistakeholder Survey on Communication of Uncertainties in Cost-Effectiveness Analysis by the Institute of Clinical and Economic Review

    Dec 1, 2025, 00:00

  • RWD64 Director Primary Data Collection

    Dec 1, 2025, 00:00

  • PCR62 Development of the Adelphi Caregiver Experience Questionnaire© (ACARE): A Novel Tool Designed to Measure and Understand the Burden and Quality of Life Impacts of the Caregiver Role

    Dec 1, 2025, 00:00

  • RWD94 Healthcare Resource Utilization Associated With Acute Pancreatitis in Patients With Familial Chylomicronemia Syndrome Treated With Olezarsen: A Post Hoc Analysis of Balance Study Data

    Dec 1, 2025, 00:00

  • RWD9 Advanced Therapies and the Unmet Need in Systemic Lupus Erythematosus Patients: Results From a Real-World Study in the United States and Germany

    Dec 1, 2025, 00:00

  • HTA113 Disparities in Market Access of ATMPs: A Comparative Analysis of HTA Outcomes Across Europe

    Dec 1, 2025, 00:00

  • HTA17 Acceptability of Early Endpoints in NICE Appraisals for Adjuvant and Neoadjuvant Oncology Therapies

    Dec 1, 2025, 00:00

  • HTA372 Will Patient Input Shape EU-Level HTA Assessments? HTA Representative Perspectives on the EU HTA Regulation

    Dec 1, 2025, 00:00

  • MSR150 Modeling Physician Prescribing Decisions Based on Patient Characteristics for Positioning of a Novel Treatment Entering a Well-Established Category

    Dec 1, 2025, 00:00

  • HTA84 Comparing ROBINS-I V2 and Downs Black for nRCTs in the Context of HTA

    Dec 1, 2025, 00:00

  • EE385 Economic Evaluation of Surfactant Therapy for Neonatal Respiratory Distress Syndrome: 5-Year Real-World Evidence on Poractant Alfa vs. Beractant From the IMSS Perspective in Mexico

    Dec 1, 2025, 00:00

  • EE23 A Model-Based Estimation of Productivity-Adjusted Life Years Due to Depression in Germany

    Dec 1, 2025, 00:00

  • RWD135 Persistence With Osteoporosis Medication Treatments Among Chinese Patients With Osteoporosis: A Retrospective Cohort Study

    Dec 1, 2025, 00:00

  • RWD90 Granulocyte-Colony Stimulating Factor (G-CSF) Reference and Biosimilar Products Using Real-World Data to Assess Data Variability Across Different Sources to Evaluate its Potential Utility in Regulatory Assessment: A Study by the Biolo ...

    Dec 1, 2025, 00:00

  • HPR46 Comparative Analysis of Access and Pricing Timelines for Innovative Medicines in the US, Europe, and Japan Pre- and Post-Pricing Reform 2021-2025

    Dec 1, 2025, 00:00

  • MSR201 The Role of Qualitative Research in Randomized Controlled Trials Involving Drugs and Medical Devices: A Systematic Mapping Review

    Dec 1, 2025, 00:00

  • PCR256 Unseen Burdens of Glycogen Storage Disease Type Ia (GSDIa) Experienced by Patients, Caregivers, and their Healthcare Team

    Dec 1, 2025, 00:00

  • SA92 Testing Automated-Prompt Engineering Strategies for Systematic Literature Review Screening

    Dec 1, 2025, 00:00

  • PCR238 The PAVING II Interview Study: Assessing Evolving Patient Preferences Regarding Gene Therapy for Hemophilia Patients

    Dec 1, 2025, 00:00

  • EPH158 Literature Review on the Economic Impact of Maternal Fetal Infections

    Dec 1, 2025, 00:00

  • CO67 Current Methodological Practices to Define Within-Patient Meaningful Change in Rare Diseases: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • SA6 Addressing Bias in Indirect Treatment Comparisons: A Framework for Identifying TEMs and PVs

    Dec 1, 2025, 00:00

  • SA89 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in the UK

    Dec 1, 2025, 00:00

  • EE188 Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in ...

    Dec 1, 2025, 00:00

  • MSR26 An Update on the Evolving Use of Artificial intelligence and Machine Learning (AI/ML) in Systematic Literature Reviews (SLRs)

    Dec 1, 2025, 00:00

  • SA79 Real-World Treatment Patterns Among Patients Newly Diagnosed With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

    Dec 1, 2025, 00:00

  • HTA69 Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation

    Dec 1, 2025, 00:00

  • MSR144 Measuring Health-Related Quality of Life and Food Insecurity in the General Population in Lebanon During the Third Worst Socioeconomic Crisis in History

    Dec 1, 2025, 00:00

  • EE708 The Five-Year Budget Impact of Introducing Semaglutide 2.4 mg for Obesity Management in Saudi Arabia: A Real-World Patient Flow and Complication-Driven Model

    Dec 1, 2025, 00:00

  • HTA179 How Impactful Is Time to Next Treatment on Health Technology Assessment Outcomes in Indolent Cancers?

    Dec 1, 2025, 00:00

  • CO171 NMAs of Systemic Therapies for Advanced Biliary Tract Cancer: A Systematic Review and Critical Appraisal Using RoB NMA

    Dec 1, 2025, 00:00

  • CO151 Indirect Treatment Comparisons in Health Technology Assessment Submissions: A Review and Critique of Best Practice

    Dec 1, 2025, 00:00

  • HTA79 Comparative Clinical Effectiveness in Skin Cancer: Lessons From HTA Decision Making in EU4, UK, and Australia

    Dec 1, 2025, 00:00

  • HSD85 Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS)

    Dec 1, 2025, 00:00

  • CO49 Clinical Outcomes In HTA Appraisal Reports Of Oncology Medicines In Portugal: A Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • EE148 Components of the Direct Cost of Topical Treatment for Chronic Wounds in Adults and Elderly: A Systematic Review

    Dec 1, 2025, 00:00

  • HTA126 Environmental Sustainability in HTA: To What Extent Are HTA Bodies Considering Environmental Considerations in Their Decision Making?

    Dec 1, 2025, 00:00

  • RWD187 Understanding Treatment Preferences in Highly Sensitized ESKD Patients: A Latent Profile Analysis of Discrete Choice Data

    Dec 1, 2025, 00:00

  • SA88 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in France, Italy, Spain, and Germany

    Dec 1, 2025, 00:00

  • EE255 Cost-Effectiveness of I-CREATE: An Inpatient Intrinsic Capacity Risk Evaluation Towards Holistic Assessment and Targeted Management of Elderly in Acute Care

    Dec 1, 2025, 00:00

  • RWD148 Real-World Associations Between Smoking Status and Genetic Driver Mutations in Metastatic Lung Cancer in US Community Oncology

    Dec 1, 2025, 00:00

  • OP14 Linking Data to Care: Mining the Pathways of Oncology

    Dec 1, 2025, 00:00

  • CO238 The Clinical Impact of Screening Blood Donations for Hepatitis E Virus in Catalonia

    Dec 1, 2025, 00:00

  • EE232 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan

    Dec 1, 2025, 00:00

  • CO57 Comparative Efficacy of First-Line (1L) Therapies for Patients With Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Updated Systematic Literature Review (SLR) and Bayesian Network Meta-Analys ...

    Dec 1, 2025, 00:00

  • MSR138 Linking Specialty Pharmacy Data With Healthcare Claims Data in a Rare Disease: Comprehensively Characterizing Patients With Hereditary Angioedema Treated With Berotralstat

    Dec 1, 2025, 00:00

  • EE554 Informing Value-Based Pricing: Cost-Effectiveness Analysis of a Hypothetical First-Line Therapy for Metastatic Pancreatic Cancer

    Dec 1, 2025, 00:00

  • EE173 Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective

    Dec 1, 2025, 00:00

  • HSD107 The Evolving Role of Pharmacists as Vaccinators in New Zealand and Denmark

    Dec 1, 2025, 00:00

  • HPR108 Global Payer Policies Potentially Impacting Pharma Pricing and Market Access Strategies: A Review of Five Key Trends Shaping Pharma Future

    Dec 1, 2025, 00:00

  • RWD139 Quality and Impact of Real-World Data in Chronic Disease Research: Insights From Retrospective Studies Using the Hospital Episode Statistics (HES) Database

    Dec 1, 2025, 00:00

  • HTA109 Development of a Unique Tool for Assessing the Feasibility of an External Control Arm Study

    Dec 1, 2025, 00:00

  • MT43 Unlocking Value Early: Insights Into NICE’s Early Value Assessments and Evidence-Generation Plans for Medical Technologies

    Dec 1, 2025, 00:00

  • SA1 A Comprehensive Assessment of Clinical Studies on Artificial Intelligence-Enabled Interventions: Uncovering Trends and Potential Implications

    Dec 1, 2025, 00:00

  • HPR197 The Disease Burden of Respiratory Syncytial Virus Among the Adult Population in Greece

    Dec 1, 2025, 00:00

  • P35 Incorporating Environmental Impacts Into Budget Impact Models: A Case Study of CAR-T Therapies in France

    Dec 1, 2025, 00:00

  • EPH50 Comparative Epidemiological Burden of Osteoarthritis in Eastern Central and Western Europe Based on the Global Burden of Disease Study 2021

    Dec 1, 2025, 00:00

  • EE645 Reforming the Delivery of Smoking Cessation: A Distributional Cost-Effectiveness Analysis of Providing Smoking Cessation as Part of Targeted Lung Cancer Screening in England

    Dec 1, 2025, 00:00

  • MT21 Generative A-Powered Extraction of Immune-Related Adverse Events From Oncology Case Reports

    Dec 1, 2025, 00:00

  • EE367 Economic Burden of the Adverse Events During Treatment of Metastatic Breast Cancer (mBC) HR(+) HER2(-) Patients in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • PCR51 Concordance Between Patient and Physician Reporting of Symptoms for Metastatic Urothelial Cancer in Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • EE61 Assessing the Economic Impact of Biosimilars in Europe: A Cost Analysis of Infliximab, Trastuzumab, and Rituximab

    Dec 1, 2025, 00:00

  • HTA110 Differences in the Reimbursement Pathway for Ultraorphan Therapies in England and Ireland

    Dec 1, 2025, 00:00

  • HTA26 Advancing Patient Involvement in Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE436 Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands

    Dec 1, 2025, 00:00

  • EE364 Economic Burden of Progressive Pulmonary Fibrosis (PPF) in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • EE65 Assessing Time Tradeoff Utilities in Health States of Organic Hypogonadotropic Hypogonadism: A Pilot Study in Brazil

    Dec 1, 2025, 00:00

  • EE236 Cost-Effectiveness of Artificial Intelligence Interventions for Musculoskeletal Disorders: Systematic Review

    Dec 1, 2025, 00:00

  • RWD184 Treatment Patterns and Healthcare Costs of Newly Diagnosed Type 1 Diabetes Patients: A Retrospective Real-World Study of Hospital Care in Tianjin, China

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • HTA14 A Review of NICE Technology Appraisals in Oncology Including Economic Evaluations With Time-Varying Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO47 Clinical Expert Opinion on the Impact of Vosoritide on Health and Function in Children With Achondroplasia

    Dec 1, 2025, 00:00

  • EE210 Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Morocco

    Dec 1, 2025, 00:00

  • EE676 Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure

    Dec 1, 2025, 00:00

  • HPR212 Extent and Causes of the Collapse in the Registration of Innovative Medications in Lebanon: A Mixed-Methods Analysis

    Dec 1, 2025, 00:00

  • EE32 A Systematic Literature Review of Cost of Illness Studies on Atrial Fibrillation With Focus on the Methodologies Economic Burden and Factors Influencing the Cost of Atrial Fibrillation Among European and North American Countries

    Dec 1, 2025, 00:00

  • PCR5 A Data-Driven Framework for Rare Disease Protocol Design: Integrating Real-World Evidence, Patient Perspectives, and Regulatory Guidance

    Dec 1, 2025, 00:00

  • EPH122 Healthcare Resource Use in Uncontrolled Hypertension: An Observational Study in England Using Electronic Health Records

    Dec 1, 2025, 00:00

  • CO152 Inefficiencies of Off-Label Therapy in the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Real-World Evidence From Europe

    Dec 1, 2025, 00:00

  • MSR197 The Effects of Pooling Treatment Effects Targeting Treatment Policy and Hypothetical Estimands With Rank-Preserving Structural Failure Time Model in Oncology Aggregate-Level Meta-Analyses

    Dec 1, 2025, 00:00

  • RWD50 Data Linkage to Support Real-World Evdence in Rare Disease

    Dec 1, 2025, 00:00

  • RWD147 Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing S ...

    Dec 1, 2025, 00:00

  • EE610 Population Impact of Performing BRCA1/2 Testing to Guide Metastatic Castration-Resistant Prostate Cancer Treatment in Spain

    Dec 1, 2025, 00:00

  • HPR38 Bridging the Gap: What Spain Can Learn From European Leaders in Digital Therapy Reimbursement

    Dec 1, 2025, 00:00

  • CO88 Effectiveness of Subcutaneous Natalizumab in Multiple Sclerosis: Real-World Evidence From a Finnish Registry Study

    Dec 1, 2025, 00:00

  • PCR2 A Collection Of Essays on Patient Centricity in Intervention Development

    Dec 1, 2025, 00:00

  • HTA373 Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies

    Dec 1, 2025, 00:00

  • HSD42 Effectiveness of Community Health Worker vs. Professional Care in Obesity Management: Preliminary Findings From a SMART Trial

    Dec 1, 2025, 00:00

  • SA66 Measurement Properties of the EQ-5D in Hematological Cancers: A Systematic Review

    Dec 1, 2025, 00:00

  • CO119 Exploring the Association Between Treatment Effects on Cure Rates and Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis (CMA) of Randomized Controlled Trials (RCTs)

    Dec 1, 2025, 00:00

  • EE219 Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal

    Dec 1, 2025, 00:00

  • HSD77 Number of Inquiries for a Second Course of Teprotumumab in the US Over Four Years

    Dec 1, 2025, 00:00

  • PCR123 Hybrid Digital Support for Patients Receiving Adalimumab Therapy for Immune-Mediated Inflammatory Disorders: 12-Month Persistence and Impact on Adherence

    Dec 1, 2025, 00:00

  • CO202 Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)

    Dec 1, 2025, 00:00

  • MSR174 Psychometric Evaluation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire Item-10 (Physical Fatigue) and Idiopathic Thrombocytopenic Purpura Bleeding Scale Using LUNA 3 Phase 3 Trial Data

    Dec 1, 2025, 00:00

  • HTA122 Effectiveness and Safety of Radiofrequency Nucleolysis for Chronic or Acute Low Back Pain

    Dec 1, 2025, 00:00

  • CO261 Using Structured Expert Elicitation to Estimate Long-Term Organ Damage Risk in an Ultrarare Condition: A STEER Case Study

    Dec 1, 2025, 00:00

  • HTA352 Using External Clinical Evidence to Inform Local Health Policy: The Tradeoff Between Early Access and Uncertainty

    Dec 1, 2025, 00:00

  • HPR229 Unintended Consequences of MFN Pricing: Global Access Risks and Revenue Impact

    Dec 1, 2025, 00:00

  • EE193 Cost-Consequence of Incorporating Single-Operator Direct Visualization Cholangioscopy in the Diagnosis of Indeterminate Biliary Strictures in Saudi Arabia

    Dec 1, 2025, 00:00

  • EE479 Gender Differences in the Economic Burden of Alcohol Use in Belgium

    Dec 1, 2025, 00:00

  • CO34 Budget Impact of a PreTRM-Guided Preventive Bundle for Preterm Birth in Low-Risk Pregnancies: A Microsimulation Study Using PRIME Trial Data

    Dec 1, 2025, 00:00

  • HPR142 Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe

    Dec 1, 2025, 00:00

  • EPH15 Analysis of Factors Behind Differences Between Official Drug Pricing and Cost-Effectiveness Evaluation in Japan and Policy Implications

    Dec 1, 2025, 00:00

  • HSD94 Real-World Evidence on Treatment Patterns and Guidelines in Patients With Advanced Merkel Cell Carcinoma Across the US and Europe

    Dec 1, 2025, 00:00

  • MSR227 Zoom Out: Simplifying Complex Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • HTA71 Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise

    Dec 1, 2025, 00:00

  • CO251 Time to and Time in Better Health States With Sotatercept for Pulmonary Arterial Hypertension: A Modeling Study

    Dec 1, 2025, 00:00

  • PCR48 Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE473 First-Line Immunotherapies for Advanced Biliary Tract Cancer: A Systematic Review of Economic Studies

    Dec 1, 2025, 00:00

  • RWD22 Assessment of Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland

    Dec 1, 2025, 00:00

  • EE228 Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India

    Dec 1, 2025, 00:00

  • HTA252 NICE Decisions in the Southwest Quadrant

    Dec 1, 2025, 00:00

  • EE253 Cost-Effectiveness of High-Dose Trivalent Influenza Vaccine in the Elderly: A Cohort-Based Economic Model From the Italian NHS Perspective

    Dec 1, 2025, 00:00

  • EPH220 Studying Paternal Drug Exposures and Offspring Outcomes: A Feasibility Assessment of 11 Large European Databases

    Dec 1, 2025, 00:00

  • MSR101 Excel Front-End, R Back-End: A Gateway to Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA

    Dec 1, 2025, 00:00

  • HPR137 Mapping PBS Drug Pathways in Australia: A Framework and Interactive Tool for Category-Specific Pricing Calculations

    Dec 1, 2025, 00:00

  • EE480 Genomic Testing for Early Breast Cancer: Assessing the Value of Next-Generation Sequencing

    Dec 1, 2025, 00:00

  • HSD52 From Agricultural Waste to Clinical Value: An Economic and Operational Analysis of Paddy Straw-Based Utensils in Malaysian Hospital

    Dec 1, 2025, 00:00

  • MSR62 Cost of Illness Studies Published Between 2010 and 2023 in Türkiye

    Dec 1, 2025, 00:00

  • MT20 Gender Inequalities in Aortic and Mitral Valve Replacement and Repair Procedures in Germany

    Dec 1, 2025, 00:00

  • MSR211 Understanding Public Values in Digital Mental Health Using the Principles, Policies, and Patients’ Framework

    Dec 1, 2025, 00:00

  • HTA52 Barriers to Reimbursement: Characteristics of Unfunded Medicines in Ireland (2006-2021)

    Dec 1, 2025, 00:00

  • SA58 Investigating Functional Status and Healthcare Resource Utilization of Patients With Cognitive Impairment Associated With Schizophrenia: Findings From a Real-World Noninterventional Study

    Dec 1, 2025, 00:00

  • EE611 Population Reference Costs for Average Total Annual Care in the UK National Health Service for 11 Common Diseases or Conditions vs. Matched Controls

    Dec 1, 2025, 00:00

  • HPR74 European and US Drug Shortages: A Critical Analysis of Key Trends and Causes

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • CO24 Balancing Innovation and Propriety: The Question of Copyright Holder’s Opinions on GenAI Usage While Localizing Their Intellectual Property

    Dec 1, 2025, 00:00

  • CO149 Increased Functional Impairment Associated With Generalized Anxiety Disorder (GAD): Findings From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT

    Dec 1, 2025, 00:00

  • HTA49 Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • MSR127 Implementing Simultaneous Maximum Acceptable Risk Thresholds (SMARTs) in Discrete Choice Experiments (DCE): A Feasible Approach to Quantify Tolerance for Multiple Risks

    Dec 1, 2025, 00:00

  • HPR129 Introducing an Access-Based Pricing Model to Determine Prices and Inform Price Negotiations for Newly Authorized Medicinal Products

    Dec 1, 2025, 00:00

  • HTA275 Provisional Listing of Digital Healthcare Applications Digas Improves Patients' Access to Healthcare in Germany

    Dec 1, 2025, 00:00

  • EE520 How Can Intravitreal Aflibercept 8 mg Impact Treatment Burden and Costs in European Patients With Diabetic Macular Edema? From Clinical Trials to Clinical Practice

    Dec 1, 2025, 00:00

  • HTA197 Importance of Decisional Context in the Health Technology Assessment (HTA) of Advanced Therapy Medicinal Products (ATMPs)

    Dec 1, 2025, 00:00

  • EE149 Comprehensive Uncertainty Assessment in Economic Evaluations of AI-Based Health Technologies: Pitfalls and Recommendations

    Dec 1, 2025, 00:00

  • RWD141 Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center

    Dec 1, 2025, 00:00

  • EE503 Healthcare Resource Use Among Patients With Chronic Rhinosinusitis With Nasal Polyps in the United Kingdom: Results of an Expert Elicitation Survey

    Dec 1, 2025, 00:00

  • EE622 Proportion of the Expenses of Over-the-Counter Equivalent Drugs Among Total Healthcare an Analysis Using the Wellness-Star∗ Database

    Dec 1, 2025, 00:00

  • HSD81 Overcoming Patient Access Barriers in Complex Conditions: Lessons From Schizophrenia for Broader Healthcare Applications

    Dec 1, 2025, 00:00

  • HPR201 The French Transitional Coverage Pathway (PECT) for Innovative Therapeutic Medical Devices: A Four-Year Retrospective Analysis

    Dec 1, 2025, 00:00

  • Methodological Challenges With Conducting Health Economic Evaluations in the Critical-Care Context

    Dec 1, 2025, 00:00

  • EE535 Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)

    Dec 1, 2025, 00:00

  • SA21 Comparative Safety of B/F/TAF vs. Other Antiretroviral Therapy Regimens for Treatment-Experienced People With HIV-1: A Systematic Literature Review and Indirect Comparisons Using Multilevel Network Meta-Regression

    Dec 1, 2025, 00:00

  • HTA233 Middle East NICE Move Towards Standardized Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE146 Comparative Analysis of Different Crown Materials for Dental Prosthesis From Budget in Wartime in Ukraine

    Dec 1, 2025, 00:00

  • HSD116 Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • HTA108 Development of a Multidimensional HTA Evaluation for the Introduction of Clesrovimab in Pediatric RSV Prevention: An Integrated Methodological Approach

    Dec 1, 2025, 00:00

  • MSR10 A Two-Stage Bayesian Approach for Real-World Cost-Effectiveness Analysis: Combining Inverse Probability Weighting With Gamma-Beta Regression Model

    Dec 1, 2025, 00:00

  • EPH19 Artificial Intelligence in Evidence Synthesis: A Systematic Review and Meta-Analysis of Emerging Biologics for Improving Skeletal Health in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • HTA55 Beyond the QALY: An Analysis of Uncaptured Benefits in NICE Oncology Technology Appraisals 2023-2025

    Dec 1, 2025, 00:00

  • EPH277 Validation Between Antidepressant Treatment Failure Proxy and PHQ-9 Score in Major Depressive Disorder Using a Linked Insurance Claims and Electronic Health Record Dataset

    Dec 1, 2025, 00:00

  • HPR76 Evaluating the Effectiveness of Interventions to Reduce Gender Disparities in Healthcare: An Overview of Literature Reviews

    Dec 1, 2025, 00:00

  • EE585 Modeling the Clinical and Economic Impact of DPP-4 Inhibitors in Uncontrolled T2D

    Dec 1, 2025, 00:00

  • P59 Challenges in Assessing Trade-offs Between Efficiency and Equity in the Use of Digital Health Applications for Stroke Care

    Dec 1, 2025, 00:00

  • EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH

    Dec 1, 2025, 00:00

  • HPR107 Global Access to Innovative Medicines in 2025: Europe’s Gaps and the UK’s Continued Decline

    Dec 1, 2025, 00:00

  • EE46 An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt

    Dec 1, 2025, 00:00

  • MSR89 Evaluating a Deep Learning Model for Classifying Pediatric Pneumonia in Israel

    Dec 1, 2025, 00:00

  • MSR25 An Integrated Web-Based Approach to Survival Analysis and Extrapolation for Economic Modeling

    Dec 1, 2025, 00:00

  • EE659 Societal and Economic Impact of Long-Acting Injectable Buprenorphine (LAIB) Compared With Standard Opioid Substitution Therapy (OST) in France

    Dec 1, 2025, 00:00

  • EE317 Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Gree A Cost Utility Analysis

    Dec 1, 2025, 00:00

  • CO64 Correlation Between Extension Survival Benefits and Incremental Costs of Oncology Drugs in Portugal: A Cross-Sectional, Regression Analysis

    Dec 1, 2025, 00:00

  • EE234 Cost-Effectiveness of an AI-Based Smartphone App for the Early Detection of Skin Cancer: A Decision Tree Analysis

    Dec 1, 2025, 00:00

  • EE339 Do The Guardrails Have Any Effect at All? An Analysis of the Impact of the 2022 FINSTG Guardrails on the German AMNOG Process

    Dec 1, 2025, 00:00

  • EPH89 Estimating the Incidence and Prevalence of Menorrhagia in the UK Using the THIN Database

    Dec 1, 2025, 00:00

  • EPH86 Estimating the Age- and Sex-Standardized Prevalence and Incidence of Depression and Anxiety in UK Adults Using the THIN Database

    Dec 1, 2025, 00:00

  • HTA224 Limited Duration vs. Treat-to-Progression Approaches for New Therapies in Hemato-oncology: Impact at HTA

    Dec 1, 2025, 00:00

  • EE289 Costs Associated With the Administration, Postinfusion Monitoring, and Management of Adverse Events (AEs) Related to Novel Drugs for Second-Line (2L+) Treatment of Small-Cell Lung Cancer (SCLC)

    Dec 1, 2025, 00:00

  • EE43 Advancing Cost-Effectiveness Modeling With R: A Flexible Approach for HTA Submissions

    Dec 1, 2025, 00:00

  • HSD19 Can Switching From Intravenous (IV) to Subcutaneous (SC) Formulations Save Time and Resources? A Service Impact Model (SIM)

    Dec 1, 2025, 00:00

  • HSD8 Assessing the Environmental Value of Semaglutide: Reduction in GHG Emissions Resulting From the Treatment of Obese Individuals With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • EE664 Societal Value of Intravitreal Injections for Retinal Vascular Diseases in the National Reimbursement Drug List in China

    Dec 1, 2025, 00:00

  • MSR78 Drifting in the Network: Catching Baseline Shifts Before They Wreck Your Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EE111 Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland

    Dec 1, 2025, 00:00

  • PCR109 Health Utility and Indirect Costs of Neuromuscular Disease Through a Patient-Centered Lens: A National Patient and Caregiver Survey

    Dec 1, 2025, 00:00

  • CO132 Herpes Zoster Hospitalization Rates in Germany: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • EPH169 Negative Symptoms in Schizophrenia: An Observational Study of Patient Characteristics Cost and Healthcare Resource Utilization From a US Healthcare Database

    Dec 1, 2025, 00:00

  • HTA91 Correlation of Intermediate Clinical Endpoints (ICES) For Overall Survival (OS) In Localized or Locally Advanced Prostate Cancer (LPC/LAPC): Analysis of Individual Real-World Data (RWD)

    Dec 1, 2025, 00:00

  • SA99 Understanding Heterogeneity in the Classification of Locally Advanced Cancer: Analysis of Clinical Trial Records From the Past 2 Years (2023-2025)

    Dec 1, 2025, 00:00

  • SA97 Therapeutic Potential of Bispecific Antibodies in Adenocarcinoma: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2025, 00:00

  • APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or Safety

    Dec 1, 2025, 00:00

  • RWD177 Switching Within vs. Outside the TNFi Class Following TNFi Failure in Patients With Crohn’s Disease (CD) in Europe: A Meta-Analysis of Real-World Outcomes

    Dec 1, 2025, 00:00

  • EE504 Healthcare Resource Use and Costs Associated With Herpes Zoster Among Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study Clinical Practice Research Datalink 2012-2019

    Dec 1, 2025, 00:00

  • PCR152 Mapping the Rare Disease Diagnostic Odyssey of Today: An Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • EE657 Societal and Economic Burden of Obesity in Bulgaria

    Dec 1, 2025, 00:00

  • HTA56 Beyond the Surfa Health Technology Assessment and Reimbursement for Inflammatory or Autoimmune Disorders With Cosmetic and Dermatological Manifestations

    Dec 1, 2025, 00:00

  • HTA123 Efficient and High-Quality Decision Making: An Exploration of Disease-Specific Reference Models at NICE

    Dec 1, 2025, 00:00

  • EE423 Estimating the Broader Societal Impact of Ocrelizumab for Multiple Sclerosis (MS) in Latin America (LATAM) Using a Social Impact Approach

    Dec 1, 2025, 00:00

  • HSD105 Subcutaneous vs. Intravenous Administration in Oncology: A Literature Review of Impacts on Patients, Providers, and Hospitals

    Dec 1, 2025, 00:00

  • HTA18 Acceptance of Artificial Intelligence in Evidence and Dossier Development by Global HTA Agencies

    Dec 1, 2025, 00:00

  • MSR104 Exploring Nonproportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology

    Dec 1, 2025, 00:00

  • PCR13 Adherence to Anti-VEGF Treatment of Patients With Age-Related Macular Degeneration of Exudative Type (nAMD) and Diabetic Macular Edema (DME) in Gree Evidence From an Expert Panel

    Dec 1, 2025, 00:00

  • MSR98 Evaluating Treatment Benefit and Tolerability Based on Responder and Time-to-Event Analysis of Patient-Reported Outcomes in Cancer Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA320 The Impact of Using England Real-World Evidence to Establish the NICE Severity Modifier in Metastatic Urothelial Carcinoma (MUC)

    Dec 1, 2025, 00:00

  • EE549 Incorporating Equity-of-Access Into Health Economic Evaluations: Surgical Task-Shifting for C-Sections in Sierra Leone

    Dec 1, 2025, 00:00

  • RWD16 An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation

    Dec 1, 2025, 00:00

  • HTA21 Adapting HTA Frameworks for Precision Medicine: Methodological Advances in the UK and EU4

    Dec 1, 2025, 00:00

  • MT48 What Is the HTA Process for Medical Technologies in Scotland?

    Dec 1, 2025, 00:00

  • HTA353 Utilization of Real-World Evidence (RWE) in AMNOG Dossiers Following the 2024 GBA Revision of Module 3 Requirements

    Dec 1, 2025, 00:00

  • HTA249 Navigating the Transition: What EU JCA Means for AMNOG Submissions in 2025 and Beyond

    Dec 1, 2025, 00:00

  • HTA128 EU HTA JCA PICO Consolidation Process Examples: Key Trends and Remaining Uncertainties

    Dec 1, 2025, 00:00

  • CO125 Garbage In, Garbage Out: Can AI Reduce the Impact of Human Error in eCOA Localized Text Migration?

    Dec 1, 2025, 00:00

  • RWD44 COPD-Asthma Overlap in Brazilian Private Healthcare: Clinical Profiles and Outcomes from a Real-World Analysis

    Dec 1, 2025, 00:00

  • EE665 Socioeconomic and Geographic Inequalities in Colorectal Cancer Care Utilization and Expenditures: A Decomposition Analysis

    Dec 1, 2025, 00:00

  • HPR11 Accelerating RTOR in Oncology: The AIM Model for Agile Trial Operations

    Dec 1, 2025, 00:00

  • EE691 The Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients With Early Breast Cancer

    Dec 1, 2025, 00:00

  • CO31 Breast Cancer Overall Survival in France

    Dec 1, 2025, 00:00

  • P61 Utilizing LLMs to Enhance Patient-Reported Outcome Measures: Application to the EQ-5D and Bolt-ons

    Dec 1, 2025, 00:00

  • HTA230 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2024

    Dec 1, 2025, 00:00

  • CO204 Real-World Efficacy Outcomes for Patients With Relapsed/Refractory Multiple Myeloma (RRMM) From the Flatiron Health Database

    Dec 1, 2025, 00:00

  • EE735 Treatment Patterns and Economic Outcomes in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US: A Real-World Claims Database Analysis

    Dec 1, 2025, 00:00

  • SA84 Screening and Diagnosis of Paroxysmal Nocturnal Hemoglobinuria in Gree Consensus Recommendations From a Multispecialty Expert Panel

    Dec 1, 2025, 00:00

  • HSD74 Missed Opportunities in the Diagnosis and Management of Stage 3 Chronic Kidney Disease in General Practi Insights From the Italian THIN Database

    Dec 1, 2025, 00:00

  • EE603 Organizational and Environmental Impact of Switching From Intravenous to Subcutaneous Immune Checkpoint Inhibitors (ICIs) in Fran A Real-World Analysis Using PMSI Data

    Dec 1, 2025, 00:00

  • P25 Optimizing the Use of Excess Hazard Models in Survival Analysis: Considering Disease Severity and Follow-up Maturity

    Dec 1, 2025, 00:00

  • EE222 Cost-Effectiveness and Budget Impact Analysis of Noninvasive Prenatal Testing (NIPT) for the Identification of Fetal Chromosomal Aneuploidies in Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • PCR247 Treatment Discontinuation in Idiopathic Pulmonary Fibrosis: A Systematic Review of Antifibrotic Drug Use and Tolerability

    Dec 1, 2025, 00:00

  • CO65 Costs and Consequences of Cardiovascular Toxicity Due to Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PT30 An Exploration of Implementing Herd Immunity Into Static Models for Economic Evaluation of Vaccines

    Dec 1, 2025, 00:00

  • EE434 Evaluating the Budget Impact of Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) in Patients With Moderate to Severe Asthma in the Saudi Healthcare System

    Dec 1, 2025, 00:00

  • MT42 The Unique Value of Detecting Preeclampsia: Comparing Health Economic Analyses of Novel Diagnostics With the ISPOR Value Flower

    Dec 1, 2025, 00:00

  • PCR40 Caregiver QALYs Deserve Better: Why It's Time for a Methodological Rethink

    Dec 1, 2025, 00:00

  • RWD136 Potential Nephrocalcinosis Risk Linked to Nusinersin: Insights from FAERS-Based Signal Detection and Molecular Docking

    Dec 1, 2025, 00:00

  • CO110 Evaluating the Repurposing Potential of Statins: Association Between Statin Use and Cognitive Decline in Patients With Mild-to-Moderate Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • HTA247 Navigating Parallel Joint Scientific Consultations Under EU HTA Regulation: Key Internal Considerations for Health Technology Developers

    Dec 1, 2025, 00:00

  • EE136 Comparative Assessment of Health-Related Quality of Life Among the Lebanese Population Pre- and Post-COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • Health-Economic Evaluation of COVID-19 Updated Booster Vaccination and Age-Related Cost Outcomes

    Dec 1, 2025, 00:00

  • MSR52 Can Generative AI Automate Health Economic Model Verification?

    Dec 1, 2025, 00:00

  • EE306 Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria

    Dec 1, 2025, 00:00

  • CO113 Evolution of MRD in Hemato-Oncology Clinical Development

    Dec 1, 2025, 00:00

  • EE357 Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in India: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR55 Digital Twins: Hype or Hope for Better Health Outcomes

    Dec 1, 2025, 00:00

  • MSR131 Improving Kidney Exchange Program Effectiveness and Equity by Using Allele and Eplet HLA Compatibility Technologies

    Dec 1, 2025, 00:00

  • EE223 Cost-Effectiveness and Budget Impact of High-Dose Trivalent Influenza Vaccine Efluelda® in Older Adults: A Greek Healthcare System Perspective

    Dec 1, 2025, 00:00

  • RWD191 Validating a Medication Adherence Index in Large Urban Population

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • EE262 Cost-Effectiveness of Modifying Cardiovascular Disease Risk Factors in Qatar Using the Productivity-Adjusted Life Years (PALY) Metric

    Dec 1, 2025, 00:00

  • EE529 Impact of Dupilumab on Mental Health Service Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • EE245 Cost-Effectiveness of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • CO23 Association Between Objective Response and Overall Survival in BRAF V600e-Mutant Metastatic Colorectal Cancer: An Analysis of the BEACON CRC Trial

    Dec 1, 2025, 00:00

  • EE703 The Economic Burden of Parkinson's Disease in the Netherlands: From Societal Impact to Investments in Health Solutions

    Dec 1, 2025, 00:00

  • HTA268 Patient-Centered PICO Scoping in EU HTA: A Pilot Study for Structured Consensus Building Using a Delphi Panel

    Dec 1, 2025, 00:00

  • HTA24 Adoption and Evidence Generation in NICE Early Value Assessments (EVA) for Medtech: Trends Across 2023-2025

    Dec 1, 2025, 00:00

  • HSD49 Evaluation of the Effectiveness of Targeted Radiofrequency Therapy in Impingement Syndrome

    Dec 1, 2025, 00:00

  • MSR22 AI-Assisted Time-to-Event Projection: A Case Study and Broader Potential

    Dec 1, 2025, 00:00

  • P62 EQ-5D Analysis in a Rare Disease: Utilities Across Disease Stages in Multiple-System Atrophy

    Dec 1, 2025, 00:00

  • EPH130 Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends

    Dec 1, 2025, 00:00

  • EE227 Cost-Effectiveness as Part of the German AMNOG Process Analyzing the 2025 SVR Proposal and Its Implementation Challenges

    Dec 1, 2025, 00:00

  • EE521 How Cost-Effectiveness and Budget Impact Drive Pricing and Reimbursement: Insights From an International Comparative Study

    Dec 1, 2025, 00:00

  • SA93 The Health Economic Case for AI in Radiology: A Systematic Review and Appraisal of Evaluation Quality and Methods

    Dec 1, 2025, 00:00

  • HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

    Dec 1, 2025, 00:00

  • PCR166 Optimizing a New Patient-Reported Outcome Instrument for Proliferative Diabetic Retinopathy: A Psychometric Study

    Dec 1, 2025, 00:00

  • HPR36 Bridging the Access Gap: The Role of Non-Public Access Partnerships for Oncology Treatments in China

    Dec 1, 2025, 00:00

  • EPH20 Assessing Pharmaceutical Innovation in Europe: Therapeutic Advances vs. Unmet Public Health Need

    Dec 1, 2025, 00:00

  • CO18 Assessment of Oncology Analog HTA Outcomes and Evidence Needs in France and Germany

    Dec 1, 2025, 00:00

  • HSD15 Bridging Systemic Access Gaps for Cancer Medicines: A Policy Perspective From the Republic of Moldova

    Dec 1, 2025, 00:00

  • EE26 A Nutrient-Dense Formula in Undernourished Children in Indonesia: An Effective Cost-Saving Strategy

    Dec 1, 2025, 00:00

  • MT29 Mortality and Economic Burden of Revisions After Proximal Femoral Fracture Fixation

    Dec 1, 2025, 00:00

  • RWD178 Systematic Review of Effectiveness of SGLT2 Inhibitors in Patients With Type 2 Diabetes With Focus on Glucose Levels, Cardiovascular Events, and Renal Function

    Dec 1, 2025, 00:00

  • HTA297 Shifts in the French HTA Transparency Committee’s Use of Indirect Comparisons: Insights From a Systematic Review of the French Transparency Committee (TC) Opinions

    Dec 1, 2025, 00:00

  • MT4 AI-Enabled Wearables for Fitness and Preventive Health

    Dec 1, 2025, 00:00

  • PCR9 A Review of Approaches to Select Instruments and Items to Measure Patient Reported Tolerability in Clinical Trials in Oncology

    Dec 1, 2025, 00:00

  • EPH193 Prevalence of Post-Traumatic Stress Disorder Among Ambulance Officers During the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • CO168 Nephrotoxicity of Antisense Oligonucleotide Therapies in Duchenne Muscular Dystrophy: A Warning or a Challenge?

    Dec 1, 2025, 00:00

  • OP10 Global Access Licensing: An Expert Interview Study with Scientists-Inventors and Directors of Technology Transfer Offices Involved in the Development and Commercialization of COVID-19 Vaccines

    Dec 1, 2025, 00:00

  • EE240 Cost-Effectiveness of Coblation Intracapsular Tonsillectomy in the Management of Sleep-Disordered Breathing and Recurrent Tonsillitis: A Brazilian Perspective

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7 (current)
  • 8
  • 9
  • 10
  • »